Johnson & Johnson closes $30B Actelion buyout

Johnson & Johnson (NYSE:JNJ) closed its $30 billion buy of Swiss biotech firm Actelion, the company reported today. The US healthcare giant bought Actelion in an all-cash deal for $280 per share.

The acquisition is expected to add $1.3 billion in sales for Johnson & Johnson in 2017, according to the company.

Get the full story at our sister site, Drug Delivery Business News.

The post Johnson & Johnson closes $30B Actelion buyout appeared first on MassDevice.

from MassDevice http://ift.tt/2rDnU6c